Finding a single new lesion in the liver on a routine scan, years after finishing treatment for colon or rectal cancer, is not a rare event. The question that usually forms first is a simple either/or: surgery or radiofrequency ablation? In practice, though, the choice is rarely settled by ranking one treatment above the other. It is worked out by passing the situation through several separate axes — the size and location of the lesion, how many lesions there are and where they sit, how much liver would remain and how well it works, and what treatment the body has already been through.
The two options do different things. A liver resection removes the lesion together with a rim of surrounding tissue, which also allows a pathologist to check whether tumor cells reach the cut edge. Thermal ablation — radiofrequency ablation (RFA) or microwave ablation (MWA) — passes a fine needle into the lesion and destroys it with heat, sparing most of the liver and avoiding a large incision, but yielding no specimen; whether the tumor was fully destroyed is judged on imaging. Stereotactic body radiotherapy (SBRT) is sometimes discussed alongside these as another local option.
Size and location come first. Heat-based treatment is generally most reliable in smaller lesions, particularly under about 3 cm, and much depends on whether a margin of a few millimeters around the tumor can also be treated. A lesion hugging a large vessel is harder to heat, because flowing blood carries warmth away. A lesion sitting close to the bile ducts, gallbladder, bowel, or diaphragm may be difficult to reach safely. Because the needle is guided by ultrasound or CT, whether the lesion is clearly visible on that particular imaging also matters in a very practical way.
Number, distribution, and liver reserve follow. Whether disease is confined to one lobe or scattered across both changes how much tissue would have to be removed, and surgery only makes sense if the remaining liver has enough volume and function to carry the load. Long courses of chemotherapy can change the liver itself; previous abdominal surgery leaves adhesions; age, heart and lung function, and blood thinners all shift the weight of anesthesia and recovery. Whether disease exists outside the liver, whether the primary site is controlled, and how long the disease-free interval has been are weighed in the same conversation.
The warning that ablation "recurs more often" is only half the story. Recurrence in this setting mixes two different things: regrowth at the edge of the treated zone, and entirely new lesions elsewhere in the liver or body. The first shrinks as lesions get smaller and better positioned; the second happens after surgery too. So the discussion tends to move away from picking a single definitive procedure and toward sequencing: how much liver should be preserved so that another treatment remains possible later, and what the next option would be if this one fails. Ablation is comparatively repeatable; resection offers tissue confirmation and a wider margin.
Before the appointment, work in order. Imaging: ask whether liver-specific contrast MRI or PET-CT has been reviewed and whether the lesion is truly solitary, and bring outside studies on disc. Records: prior operative and pathology reports, chemotherapy agents and cumulative cycles, the trend in tumor markers such as CEA, and recent liver function values, on one page. Medications: anticoagulants, blood pressure and diabetes drugs, supplements. Questions: what specifically favors resection or ablation in this lesion; whether the remnant liver is sufficient and whether a laparoscopic or robotic approach is possible; how the needle would be guided and what margin is planned; what the next step is if the treatment fails; and whether chemotherapy belongs before or after. Logistics: hospital stay and recovery differ between the two, so work and caregiving arrangements belong in the decision.
These decisions are usually settled in a multidisciplinary meeting involving surgery, medical oncology, radiology, and radiation oncology. No approach can promise a cure or guarantee no recurrence, but understanding which axis pushed the recommendation one way makes the follow-up schedule and the next step far clearer.
This article is general information and does not diagnose or recommend treatment for any individual. Please discuss decisions about your own care with your medical team.